[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564810":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":23,"centralContacts":24,"locations":34,"responsibleParty":54,"collaborators":23,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":23,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":23,"studyType":71,"phases":72,"briefSummary":75,"conditions":76,"keywords":23,"overallStatus":37,"whyStopped":23,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Dow University of Health Sciences","OTHER",[8,13],{"label":9,"type":9,"description":10,"interventionNames":11},"EXPERIMENTAL","Only the test side that will be intervened with i-PRF will be obtained from the upper liquid layer and will be placed in dental injectors using a 27 mm gauged needle. During the first application the amount of i-PRF will be standardized as 4 mL and injected through intra-ligamental into the disto-buccal and disto-palatal side of the canine tooth (2 mL for each side) and at the time of second intervention i.e 8th week form the baseline intramucosal injection will be administered equidistant from the maxillary canine and second premolar, 2ml on buccal side and 2ml on palatal side) after anesthetizing the region with local anesthesia (2% Lignocaine).",[12],"Biological: Platelet rich fibrin",{"label":14,"type":15,"description":16,"interventionNames":17},"CONTROL","PLACEBO_COMPARATOR","On control side saline was injected using a 27 mm gauged needle. During the first application the saline was injected through intra-ligamental into the disto-buccal and disto-palatal side of the canine tooth (2 mL for each side) and at the time of second intervention i.e 8th week form the baseline intramucosal injection will be administered equidistant from the maxillary canine and second premolar, 2ml on buccal side and 2ml on palatal side) after anesthetizing the region with local anesthesia (2% Lignocaine).",[12],[19],{"type":20,"name":21,"description":10,"armGroupLabels":22,"otherNames":23},"BIOLOGICAL","Platelet rich fibrin",[14,9],null,[25,31],{"name":26,"role":27,"phone":28,"phoneExt":29,"email":30},"Fahad Iqbal Farooqui, bds","CONTACT","021-111113847","7020","fahad.iqbal@duhs.edu.pk",{"name":32,"role":27,"phone":28,"phoneExt":29,"email":33},"Hareem Sultan, Bds, Fcps, Morth","hareem.sultan@duhs.edu.pk",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Dow university of health sciences","RECRUITING","Karachi","Sindh","74200","Pakistan","PK",{"type":44,"coordinates":45},"Point",[46,47],67.0104,24.8608,{"lat":47,"lon":46},[50,52],{"name":51,"role":27,"phone":28,"phoneExt":29,"email":30},"Fahad Iqbal, bds",{"name":53,"role":27,"phone":28,"phoneExt":29,"email":33},"hareem Sultan, Bds,Fcps,Morth",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"PRINCIPAL_INVESTIGATOR","Fahad Iqbal Farooqui","Lecturer","100564810","phase-1-evaluation-of-effect-of-platelet-rich-fibrin-on-orthodontic-tooth-movement-a-split-mouth-randomised-controlled-trial-100564810",false,"NCT06634017","Evaluation of Effect of Platelet-Rich Fibrin on Orthodontic Tooth Movement: a Split Mouth Randomised Controlled Trial","Inclusion Criteria:\n\n* Patients who give written consent to participate in the research\n* Orthodontic patients with good oral hygiene\n* Patients with periodontal probing depths≤3 mm with no bone loss\n* Patients undergoing orthodontic treatment with fixed appliance and requiring upper first premolar extraction followed by canine retraction\n* Patients treated with canine retraction utilizing maximum anchorage in the maxillary arch from trans-palatal arch anchorage device\n* Patients with mild to moderate crowding in maxillary arch\n* Patients with no previous history of orthodontic treatment\n\nExclusion Criteria:\n\n* patients who are smokers, health compromised (such as diabetics, with bone disorders, immunocompromised, known with blood dyscrasias) will be excluded from the trial. Patients with drug history of non-steroidal anti-inflammatory drugs, anti-inflammatory (in last 30 days), antibiotic therapy in last 3 months and those women who are pregnant will also be excluded.\n\nOther exclusion criteria will be patients with hypodontia, impacted\u002Fectopic canines, extracted first molars, and patients who may discontinue the trial with or without assigning any reasons and those not consenting to participate in the research.",true,"ALL","18 Years","45 Years",{"count":69,"type":70},15,"ESTIMATED","INTERVENTIONAL",[73,74],"PHASE1","PHASE2","it is a randomized control trial and aims at investigating the effects of PRF on rate of tooth movement and root length to be tested on larger sample size of pakistani population",[77],"Rate of Tooth Movement in Orthodontic Patients","2024-10-07",{"date":80,"type":81},"2024-10-09","ACTUAL",{"date":83,"type":81},"2024-04-25",{"date":85,"type":70},"2025-04-24",{"name":5,"class":6},1]